AGÕæÈ˹ٷ½

Atlas Lithium (ATLX) filed its Q2-25 Form 10-Q. The company remains pre-production, with only quartzite sales reported.

• Revenue: $31.8k in Q2 (-83% YoY); $57.0k YTD (-85% YoY).
• Net loss: Q2 â€�$6.3 m vs â€�$10.0 m LY; YTD â€�$16.5 m vs â€�$23.1 m, helped by lower stock-based comp and exploration spend.
• Cash & liquidity: Cash fell to $13.9 m (-$1.7 m YTD). Operating cash burn was $8.3 m; capex/exploration another $6.3 m, partly offset by $12.9 m raised via the Nov-24 ATM program (2.47 m shares).
• Balance sheet: Total assets $63.3 m (+9% YTD) driven by capex on Neves project. Equity rose to $26.2 m from $22.0 m. Convertible debt stable at $9.94 m (6.5% coupon, $28.225 conversion price).
• Dilution: Shares outstanding increased 18% to 18.8 m; 19.6 m as of 31-Jul-25.
• Derivative items: NDF hedge produced $0.43 m OCI gain; conversion-feature liability fell to $7k.
• Operational milestones: â€� Mining concession granted for core Neves right (1,536 ha). â€� Definitive Feasibility Study (issued 30-Jul-25) projects 146 ktpa spodumene, $57 m capex, after-tax IRR 145%, 11-month payback, cash cost $489/t (lowest quartile).

Outlook: Management touts strong DFS economics, but substantial funding will be required to cover the $57 m build-out while sustaining a high cash burn. Continued reliance on equity raises implies further dilution risk.

Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).

• Shares owned: 1,362,503 common shares.
• Ownership percentage: 6.69 % of the 20,368,982 shares outstanding as of 30 Apr 2025.
• Control rights: The Reporting Persons hold shared voting and dispositive power over all shares; they report zero sole voting/dispositive power, indicating no unilateral control.
• Date of event: 15 Jul 2025; filing signed 22 Jul 2025.
• Filer status: Perceptive Advisors is an investment adviser (IA); Edelman is a U.S. individual; Master Fund is Cayman-based.

The certification states the securities were not acquired to influence control, confirming a passive investment posture. Perceptive’s >5 % position may draw investor attention because the healthcare-focused fund is considered a sophisticated life-sciences investor.

Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Dean J. Mitchell received a new stock option grant for 10,520 common shares on 26 June 2025. The option carries an exercise price of $44.04 and expires on 26 June 2035. Vesting occurs in twelve equal monthly installments over one year starting on the grant date. No common shares were bought or sold; this is purely an equity-based compensation award that increases Mr. Mitchell’s derivative holdings to 10,520 options, all held directly. The transaction is routine and designed to align director incentives with shareholder interests, with minimal immediate balance-sheet or ownership impact on PRAX.

Praxis Precision Medicines (PRAX) � Form 4 Insider Activity

Director William D. Young disclosed the grant of a stock option for 10,520 common shares on 26-Jun-2025 at an exercise price of $44.04. The option vests in twelve equal monthly installments over one year, beginning on the grant date, and expires on 26-Jun-2035. No open-market purchases or sales of common stock were reported. Following the transaction, Mr. Young beneficially owns 10,520 derivative securities linked to PRAX common shares. The filing was executed on 27-Jun-2025.

Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Gregory Norden received an option grant on 26 Jun 2025.

• Derivative security issued: Non-qualified stock option covering 10,520 common shares with an exercise price of $44.04.
• Vesting schedule: Vests in twelve equal monthly instalments beginning 26 Jun 2025, fully vested after one year.
• Expiration: 26 Jun 2035 (10-year term).
• Ownership impact: Following the grant, Norden beneficially owns 10,520 derivative securities (stock options) directly; no non-derivative share movement is reported.

The filing represents a routine equity incentive award to a board member and does not indicate any open-market purchase or sale of PRAX shares.

Praxis Precision Medicines, Inc. (PRAX) â€� Form 4 insider filing

Director Jill DeSimone received a new option grant on 26 June 2025. The grant covers 10,520 shares of common stock at an exercise price of $44.04 and expires on 26 June 2035. Vesting is scheduled in twelve equal monthly installments over one year beginning on the grant date, aligning compensation with near-term company performance. After this transaction Ms. DeSimone holds 10,520 derivative securities directly. No common-stock transactions, sales, or additional option exercises were reported.

The filing represents a routine equity incentive for a non-employee director and does not change PRAX’s share count in a material way. The transaction code "A" confirms an acquisition of options rather than an open-market purchase, so immediate cash outlay or insider buy-signal implications are minimal.

Praxis Precision Medicines, Inc. (PRAX) reported a routine insider equity award through a Form 4 filed on 27 June 2025. Director Jeffrey Chodakewitz received a grant of 10,520 stock options on 26 June 2025 at an exercise price of $44.04 per share. The options vest in 12 equal monthly installments over one year beginning the grant date and carry an expiration date of 26 June 2035. No open-market purchases or sales of common stock were disclosed, and Mr. Chodakewitz’s direct derivative holdings after the transaction total 10,520 options. The filing reflects a standard compensation-related award rather than a change in the director’s economic exposure to outstanding common shares.

Praxis Precision Medicines, Inc. (PRAX) � Form 4 Insider Transaction

Director Merit Ester Cudkowicz reported the grant of 10,520 stock options on 26 June 2025. The options carry an exercise price of $44.04 and expire on 26 June 2035. Ownership is recorded as direct.

Vesting schedule: the award vests in 12 equal monthly installments over one year, beginning 26 June 2025, resulting in full vesting by 26 June 2026. Following the grant, the reporting person beneficially owns 10,520 derivative securities; no common-stock transactions were disclosed in Table I.

The filing is routine compensation-related and does not involve any sale or purchase of shares. It primarily signals ongoing alignment of director incentives with shareholder interests and does not immediately affect PRAX’s capital structure, earnings, or liquidity.